Therapeutic Options for Resistant Lupus Nephritis

Seminars in Arthritis and Rheumatism

Volumn 36, Issue 2, 2006, Pages 71-81

  Mok, Chi Chiu ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

biologics; glomerulonephritis; immunomodulatory; lupus erythematosus; modalities

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BELIMUMAB; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; EPRATUZUMAB; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; CONSENSUS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; GINGIVA HYPERTROPHY; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOADSORPTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; METABOLIC DISORDER; NEPHROTOXICITY; NEUROLOGIC DISEASE; OVARY DISEASE; OVARY INSUFFICIENCY; PATIENT COMPLIANCE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RHEUMATOID ARTHRITIS; SMOKING CESSATION; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS;

EID: 33749143155     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2006.04.008     Document Type: Article

References (107)

1. Bastian H.M., Roseman J.M., McGwin Jr. G., Alarcon G.S., Friedman A.W., Fessler B.J., et al., LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Systemic lupus erythematosus in three ethnic groups XII. Risk factors for lupus nephritis after diagnosis. Lupus 11 (2002) 152-160
2. Mok C.C., and Tang S.S.K. Incidence and predictive factors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 117 (2004) 791-795
3. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
4. Donadio Jr. J.V., Hart G.M., Bergstralh E.J., and Holley K.E. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 4 (1995) 109-115
5. Mok C.C., Wong R.W., and Lau C.S. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis 34 (1999) 315-323
6. Bono L., Cameron J.S., and Hicks J.A. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92 (1999) 211-218
7. Neumann K., Wallace D.J., Azen C., Nessim S., Fichman M., Metzger A.L., et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 25 (1995) 47-55
8. Bakir A.A., Levy P.S., and Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 24 (1994) 159-171
9. Dooley M.A., Hogan S., Jennette C., and Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 51 (1997) 1188-1195
10. Nossent H.C., and Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephritis. Rheumatology (Oxford) 39 (2000) 969-974
11. Korbet S.M., Lewis E.J., Schwartz M.M., Reichlin M., Evans J., Rohde R.D., and Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35 (2000) 904-914
12. Mok C.C. Prognostic factors in lupus nephritis. Lupus 14 (2005) 39-44
13. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med (in press).
14. Mok C.C., Ying K.Y., Tang S., Leung C.Y., Lee K.W., Ng W.L., et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50 (2004) 2559-2568
15. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., de Ramon Garrido E., Danieli M.G., et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50 (2004) 3934-3940
16. Chan T.M., Tse K.C., Tang C.S., Lai K.N., and Li F.K. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14 (2005) 265-272
17. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 54 (2006) 421-432
18. Boumpas D.T., and Balow J.E. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 7 (1998) 622-629
19. Austin III H.A., Klippel J.H., Balow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. New Engl J Med 314 (1986) 614-619
20. Mok C.C., Ho C.T.K., Chan K.W., Lau C.S., and Wong R.W.S. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46 (2002) 1003-1013
21. Somers E.C., Marder W., Christman G.M., Ognenovski V., and McCune W.J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52 (2005) 2761-2767
22. Pavletic S.Z., and Illei G.G. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 19 (2005) 839-858
23. Jayne D., Passweg J., Marmont A., Farge D., Zhao X., Arnold R., et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13 (2004) 168-176
24. Brodsky R.A., Petri M., Smith B.D., Seifter E.J., Spivak J.L., Styler M., et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 129 (1998) 1031-1035
25. Petri M., Jones R.J., and Brodsky R.A. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48 (2003) 166-173
26. Petri M, Brodsky R, Jones R, Brodsky I, Magder L. High-dose cyclophosphamide vs monthly cyclophosphamide: eighteen month results. [abstract]. ACR meeting 2005 (abstract 1993).
27. Chan T.M., Tse K.C., Tang C.S., Mok M.Y., Li F.K., and Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16 (2005) 1076-1084
28. Ong L.M., Hooi L.S., Lim T.O., Goh B.L., Ahmad G., Ghazalli R., et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10 (2005) 504-510
29. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New Engl J Med 353 (2005) 2219-2228
30. Briggs W.A., Choi M.J., and Scheel Jr. P.J. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31 (1998) 213-217
31. Glicklich D., and Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 32 (1998) 318-322
32. Gaubitz M., Schorat A., Schotte H., Kern P., and Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8 (1999) 731-736
33. Fu Y.F., and Liu G.L. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Clin Nephrol 55 (2001) 318-321
34. Buratti S., Szer I.S., Spencer C.H., Bartosh S., and Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 28 (2001) 2103-2108
35. Dooley M.A., Cosio F.G., Nachman P.H., Falkenhain M.E., Hogan S.L., Falk R.J., et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10 (1999) 833-839
36. Kingdon E.J., McLean A.G., Psimenou E., Davenport A., Powis S.H., Sweny P., et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 10 (2001) 606-611
37. Kapitsinou P.P., Boletis J.N., Skopouli F.N., Boki K.A., and Moutsopoulos H.M. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 43 (2004) 377-380
38. Pisoni C.N., Sanchez F.J., Karim Y., Cuadrado M.J., D'Cruz D.P., Abbs I.C., et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 32 (2005) 1047-1052
39. Karim M.Y., Alba P., Cuadrado M.J., Abbs I.C., D'Cruz D.P., Khamashta M.A., et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 41 (2002) 876-882
40. Favre H., Miescher P.A., Huang Y.P., Chatelanat F., and Mihatsch M.J. Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 9 Suppl 1 (1989) 57-60
41. Tam L.S., Li E.K., Leung C.B., Wong K.C., Lai F.M., Wang A., et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 91 (1998) 573-580
42. Fu L.W., Yang L.Y., Chen W.P., and Lin C.Y. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 37 (1998) 217-221
43. Dostal C., Tesar V., Rychlik I., Zabka J., Vencovsky J., Bartunkova J., et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 7 (1998) 29-36
44. Ferrario L., Bellone M., Bozzolo E., Baldissera E., and Sabbadini M.G. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology (Oxford) 39 (2000) 218-220
45. Scott L.J., McKeage K., Keam S.J., and Plosker G.L. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63 (2003) 1247-1297
46. Politt D., Heintz B., Floege J., and Mertens P.R. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 62 (2004) 49-53
47. Duddridge M., and Powell R.J. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56 (1997) 690-692
48. Mok C.C., Tong K.H., To C.H., Siu Y.P., and Au T.C. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 68 (2005) 813-817
49. Mok C.C., Ho C.T., Siu Y.P., Chan K.W., Kwan T.H., Lau C.S., et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38 (2001) 256-264
50. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 44 (2001) 1984-1992
51. Remer C.F., Weisman M.H., and Wallace D.J. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10 (2001) 480-483
52. Tam L.S., Li E.K., Wong C.K., Lam C.W., and Szeto C.C. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13 (2004) 601-604
53. Tam L.S., Li E.K., Wong C.K., Lam C.W., Li W.C., and Szeto C.C. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65 (2006) 417-418
54. Gensburger D., Kawashima M., Marotte H., Kanitakis J., and Miossec P. Lupus erythematosus with leflunomide: induction or reactivation?. Ann Rheum Dis 64 (2005) 153-155
55. Goeb V., Berthelot J.M., Joly P., Mejjad O., deq Uatrebarbes J., Reynaud-Hautin C., et al. Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 44 (2005) 823-824
56. Chan S.K., Hazleman B.L., and Burrows N.P. Subacute cutaneous lupus erythematosus precipitated by leflunomide. Clin Exp Dermatol 30 (2005) 724-725
57. Toubi E., Kessel A., and Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 66 (2005) 395-402
58. Boletis J.N., Ioannidis J.P., Boki K.A., and Moutsopoulos H.M. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354 (1999) 569-570
59. Orbach H., Tishler M., and Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 34 (2004) 593-601
60. Levy Y., Sherer Y., George J., Rovensky J., Lukac J., Rauova L., et al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29 (2000) 321-327
61. Lin C.Y., Hsu H.C., and Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53 (1989) 303-310
62. Winder A., Molad Y., Ostfeld I., Kenet G., Pinkhas J., and Sidi Y. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 20 (1993) 495-498
63. Lewis E.J., Hunsicker L.G., Lan S.P., Rohde R.D., Lachin J.M., and The Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326 (1992) 1373-1379
64. Euler H.H., Schroeder J.O., Harten P., Zeuner R.A., and Gutschmidt H.J. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 37 (1994) 1784-1794
65. Wallace D.J., Goldfinger D., Pepkowitz S.H., Fichman M., Metzger A.L., Schroeder J.O., et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apheresis 13 (1998) 163-166
66. Danieli M.G., Palmieri C., Salvi A., Refe M.C., Strusi A.S., and Danieli G. Synchronized therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apheresis 17 (2002) 72-77
67. Huang D.F., Tsai S.T., and Wang S.R. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci 15 (1994) 283-288
68. Wu C.T., Fu L.S., Wen M.C., Hung S.C., and Chi C.S. Lupus vasculopathy combined with acute renal failure in lupus nephritis. Pediatr Nephrol 18 (2003) 1304-1307
69. Blake J.S., and Butani L. Rapidly progressive lupus glomerulonephritis and concomitant microangiopathy in an adolescent. Lupus 11 (2002) 533-535
70. Braun N., Erley C., Klein R., Kotter I., Saal J., and Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 15 (2000) 1367-1372
71. Pfueller B., Wolbart K., Bruns A., Burmester G.R., and Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 44 (2001) 1962-1963
72. Suzuki K. The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus. Ther Apher 4 (2000) 239-243
73. Stummvoll G.H., Aringer M., Smolen J.S., Schmaldienst S., Jimenez-Boj E., Horl W.H., et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 64 (2005) 1015-1021
74. Davis Jr. J.C., Austin III H., Boumpas D., Fleisher T.A., Yarboro C., Larson A., et al. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 41 (1998) 335-343
75. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
76. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
77. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (in press).
78. Marks S.D., Patey S., Brogan P.A., Hasson N., Pilkington C., Woo P., et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52 (2005) 3168-3174
79. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64 (2005) 913-920
80. van Vollenhoven R.F., Gunnarsson I., Welin-Henriksson E., Sundelin B., Osterborg A., Jacobson S.H., et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 33 (2004) 423-427
81. Fra G.P., Avanzi G.C., and Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 12 (2003) 783-787
82. Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., and Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 12 (2003) 798-800
83. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
84. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
85. Lambotte O., Durbach A., Kotb R., Ferlicot S., Delfraissy J.F., and Goujard C. Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol 64 (2005) 73-77
86. Edelbauer M., Jungraithmayr T., and Zimmerhackl L.B. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol 20 (2005) 811-813
87. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
88. Gabay C., Cakir N., Moral F., Roux-Lombard P., Meyer O., Dayer J.M., et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24 (1997) 303-308
89. Malide D., Russo P., and Bendayan M. Presence of tumor necrosis factor and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 26 (1995) 558-564
90. Herrera-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., and Avalos-Diaz E. Renal expression of IL-6 and TNF alpha genes in lupus nephritis. Lupus 7 (1998) 154-158
91. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50 (2004) 3161-3169
92. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al., BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003) 719-727
93. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 3 (2002) 1017-1023
94. Mok C.C., Ying K.Y., Lau C.S., Yim C.W., Ng W.L., Wong W.S., et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 43 (2004) 269-276
95. Moroni G., Maccario M., Banfi G., Quaglini S., and Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis 31 (1998) 681-686
96. Hallegua D., Wallace D.J., Metzger A.L., Rinaldi R.Z., and Klinenberg J.R. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9 (2000) 241-251
97. Radhakrishnan J., Kunis C.L., D'Agati V., and Appel G.B. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42 (1994) 147-154
98. Spetie D.N., Tang Y., Rovin B.H., Nadasdy T., Nadasdy G., Pesavento T.E., et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 66 (2004) 2411-2415
99. Chan T.M., Li F.K., Hao W.K., Chan K.W., Lui S.L., Tang S., et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 8 (1999) 545-551
100. Karim M.Y., Pisoni C.N., Ferro L., Tungekar M.F., Abbs I.C., D'Cruz D.P., et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44 (2005) 1317-1321
101. Boumpas D.T., Tassiulas I.O., Fleisher T.A., Vaughan E., Piscitelli S., Kim Y., et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol 52 (1999) 67-75
102. Ruggenenti P., Chiurchiu C., Brusegan V., Abbate M., Perna A., Filippi C., et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14 (2003) 1851-1857
103. Chuahirun T., Khanna A., Kimball K., and Wesson D.E. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis 41 (2003) 13-21
104. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G., de Jong P.E., et al., AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139 (2003) 244-252
105. Ruggenenti P. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 24 (2004) 158-167
106. Wolf G., and Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67 (2005) 799-812
107. Tse K.C., Li F.K., Tang S., Tang C.S., Lai K.N., and Chan T.M. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14 (2005) 947-952